/PRNewswire/ Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan 2021 Global High Yield &.
Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy
News provided by
Share this article
Share this article
LAUSANNE, Switzerland, Feb. 17, 2021 /PRNewswire/ Onward Therapeutics SA (Onward) announced today the execution of a strategic investment in EMERCell SAS, Montpellier, France, a company that has developed a platform technology to produce off-the-shelf natural killer (NK) cells. The undisclosed amounts of the equity investment in three instalments, allow Onward to become the majority shareholder. Dr. Alain Herrera, Chief Medical Officer of Onward, has been elected Chairperson of the Board of EMERCell.
In the era of cancer immunotherapy, NK cells are one of the immune cells that can be harnessed, along with antibodies or genetic modifications to kill tumor cells. One major advantage of EMERCell s technology is its versatility in offering allogeneic, instead of autologous treatment by CAR-T or CAR-NK cell therapy. Onwar
WelbeHealth Expands Executive Team with Key New Hire
Sepideh Chegini, MD, Joins WelbeHealth as Chief Medical Officer
News provided by
Share this article
Share this article
MENLO PARK, Calif., Feb. 17, 2021 /PRNewswire/ WelbeHealth, an all-inclusive medical care provider for frail elderly, helping them live independently in their own home, is proud to welcome Sepideh Chegini, MD, as Chief Medical Officer.
Dr. Chegini will oversee clinical care delivery, ensuring that participants receive the highest standard of medical care, while upholding WelbeHealth values and enhancing the experience of its teams. Under her leadership, WelbeHealth programs will further expand into underserved communities. We are grateful to have Sepi join WelbeHealth to help us ensure the highest quality care for our frail and vulnerable seniors, said Si France, MD, Founder and CEO of WelbeHealth. Sepi has an extensive track record of leading and innovating within value-based care to drive exception
ELLKAY Names Gretchen Tegethoff As Regional Vice President Of Strategic Relationships
News provided by
Share this article
Share this article
ELMWOOD PARK, N.J., Feb. 17, 2021 /PRNewswire/ ELLKAY, a leader in healthcare connectivity since 2002, announced Gretchen Tegethoff has joined its team as the new Regional Vice President of Strategic Relationships. Tegethoff has extensive experience in the healthcare IT industry, having served both as CIO of The George Washington University Hospital and as Vice President of the College of Healthcare Information Management Executives (CHIME). Tegethoff brings her deep knowledge of the challenges hospital IT leaders face to provide strategic partnerships to ELLKAY s partners, particularly as organizations must embrace progressive new technologies to drive healthcare forward at a rapid pace.
Immunovia Full Year Report 2020
News provided by
Share this article
LUND, Sweden, Feb. 17, 2021 /PRNewswire/
Immunovia has today published its Full Year Report for January - December 2020. It is available on Immunovia s website. Immunovia is approaching commercial breakthrough: A sales start is planned for the first quarter of 2021. We look forward to helping patients through early detection of pancreatic cancer.
All Immunovia employees are incredibly proud of the progress we have made in 2020, especially with regard to the October 2020 milestone when we were able to document 94 percent accuracy for IMMray™ PanCan-d, the company s first blood test for the diagnosis of pancreatic cancer in the early stages of the disease when it is still possible to conduct surgery. The result opens the way for significantly improved care and survival of patients suffering from this deadly disease.